kabutan

Nxera Pharma shares continue to rise on milestone achievement in drug discovery partnership with AbbVie

Tue Apr 21, 2026 9:42 am JST Catalyst

Shares of NXERA PHARMA CO., LTD. <4565> continued their upward trajectory on 21st following the disclosure of a 10 million dollars milestone payment from its partner ABBVIE . The achievement marks the third research milestone reached under their joint program focused on neurological disorders. Revenue from the payment is expected to be recognized primarily within the fiscal year ending December 2026, providing a positive boost to the current year's financial outlook.

Under the 2022 drug discovery and license option agreement, Nxera Pharma stands to receive up to 40 million dollars in initial development incentives. The potential total value of the partnership remains substantial, with up to 1.2 billion dollars in milestones tied to option exercises and the successful attainment of development and sales goals, complemented by tiered royalties on global net sales. Market participants view this latest milestone as further validation of Nxera’s proprietary GPCR-targeted discovery platform.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles